| Literature DB >> 27519157 |
Abstract
The goal of re-programming the host immune system to target malignancy with durable anti-tumour clinical responses has been speculated for decades. In the last decade such speculation has been transformed into reality with unprecedented and durable responses to immune checkpoint inhibitors seen in solid tumours. This mini-review considers the mechanism of action of immune modulating agents and the potential for combination with radiotherapy in the treatment of non-small cell lung cancer.Entities:
Keywords: Checkpoint inhibition; NSCLC; immunotherapy; radiotherapy
Mesh:
Year: 2016 PMID: 27519157 DOI: 10.1016/j.clon.2016.07.014
Source DB: PubMed Journal: Clin Oncol (R Coll Radiol) ISSN: 0936-6555 Impact factor: 4.126